Gastrointestinal Cancer

Two in 3 patients treated with PD-1 or PD-L1 inhibitors experienced at least 1 AE and 1 in 7 patients experienced at least 1 grade ≥3 AE, according to a systematic review and meta-analysis of clinical trials and study updates published through December 15, 2018.

Gazala N. Khan, MD, highlights the recent headway made in hepatocellular carcinoma and discusses the remaining challenges.

The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses the role of regorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

Emil Cohen, MD, discusses the locoregional therapies available for the treatment of patients with hepatocellular carcinoma and offers insight into optimal strategies.

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Barbara Ann Karmanos Cancer Institute, discusses research questions with Lutathera in the treatment of patients with neuroendocrine tumors.

Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.

With multiple biomarker-directed clinical trials for metastatic CRC expected to produce data within the next few years, experts in gastrointestinal oncology who took part in a recent OncLive Peer Exchange® program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Philip A. Philip, MD, PhD, FRCP, discusses recent studies that have impacted locally advanced pancreatic cancer treatment and shared key updates in the neuroendocrine tumors paradigm.

Gazala N. Khan, MD, gastrointestinal medical oncologist, Henry Ford Health System, discusses sequencing strategies in advanced hepatocellular carcinoma.

Ivosidenib demonstrated a statistically significant improvement in progression-free survival by independent radiology review compared with placebo in patients with IDH1-mutant previously treated cholangiocarcinoma.

Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.

A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses emerging combination therapies in hepatocellular carcinoma (HCC).

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

Bassel El-Rayes, MD, further discusses the role of locoregional approaches in borderline and unresectable patients with metastatic colorectal cancer.

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

There has been a significant evolution in the care of patients with metastatic colorectal cancer over the past 20 years. However, this is only the tip of the iceberg and we are going to see more and more subgroups being defined and refined with many more rationally targeted agents matching these alterations.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.